Efficacy and Safety of Peginterferon in ET and PV.

Summary

This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Eligible participants will receive a subcutaneous injection of Peginterferon α-2b 180 mcg once a week and follow-up，and efficacy and safety will be evaluated.

Timeline

Start

2024-11-20

Primary completion

2026-11-20

Completion

2027-11-20

Drugs

Indications